http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112245403-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035 |
| filingDate | 2020-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112245403-B |
| titleOfInvention | Phosphodiesterase-4 inhibitor and oral solid composition thereof |
| abstract | The invention relates to a phosphodiesterase-4 inhibitor and an oral solid composition thereof, wherein the composition is an apremilast tablet and comprises the following components: apremilast, lactose, microcrystalline cellulose, magnesium stearate, and the like. The tablet is prepared by a method comprising the following steps: uniformly mixing apremilast, lactose, microcrystalline cellulose and the like, and preparing granules by a dry method by using a compression roller device; adding the balance of croscarmellose sodium into the obtained granules, uniformly mixing, then adding magnesium stearate, and uniformly mixing; tabletting the obtained mixed granules on a tabletting machine to obtain tablets in a plain tablet form; optionally coating the obtained plain tablets with a coating solution to obtain coated tablets. The tablets of the invention can be used for the treatment of adult patients with active psoriatic arthritis, adult patients with moderate to severe plaque psoriasis who are suitable for phototherapy or systemic therapy, adult patients with oral ulcers associated with behcet's disease; and the tablet exhibits excellent technical effects as described in the specification. |
| priorityDate | 2020-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 175.